These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2569825)

  • 1. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
    Pool JL; Taylor AA; Nelson EB
    Am J Med; 1989 Aug; 87(2A):57S-61S. PubMed ID: 2569825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
    Pool JL
    Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL; Lenz ML; Taylor AA
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacotherapeutics of doxazosin.
    Taylor SH
    Am J Med; 1989 Aug; 87(2A):2S-11S. PubMed ID: 2569822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
    Pool JL
    Am Heart J; 1991 Jan; 121(1 Pt 2):251-9; discussion 259-60. PubMed ID: 1824647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
    Trost BN; Weidmann P; Riesen W; Claessens J; Streulens Y; Nelemans F
    Am J Cardiol; 1987 May; 59(14):99G-104G. PubMed ID: 2884861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins.
    Ames RP; Kiyasu JY
    J Clin Pharmacol; 1989 Feb; 29(2):123-7. PubMed ID: 2565917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
    Frick MH; Cox DA; Himanen P; Huttunen M; Pitkäjärvi T; Pörsti P; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
    Am J Cardiol; 1987 May; 59(14):61G-67G. PubMed ID: 2884854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with doxazosin in general medical practice.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1748-57. PubMed ID: 2904745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
    Lehtonen A; Himanen P; Saraste M; Niittymäki K; Marniemi J
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):77S-81S. PubMed ID: 2939871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
    Mazzola C; Guerrasio E
    Am Heart J; 1988 Dec; 116(6 Pt 2):1797-801. PubMed ID: 2904753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
    Talseth T; Westlie L; Daae LN
    J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys.
    Karge WH; Kowala MC; Weiner EJ; Nicolosi RJ
    J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S25-9; discussion S29-30. PubMed ID: 2471012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk.
    Daae LN; Westlie L
    Blood Press; 1998 Jan; 7(1):39-45. PubMed ID: 9551876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
    Hirano T; Yoshino G; Kashiwazaki K; Adachi M
    Am J Hypertens; 2001 Sep; 14(9 Pt 1):908-13. PubMed ID: 11587157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive drugs and blood lipids: the Oslo study.
    Leren P; Eide I; Foss OP; Helgeland A; Hjermann I; Holme I; Kjeldsen SE; Lund-Larsen PG
    J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S222-4. PubMed ID: 6177960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
    Talseth T; Westlie L; Daae L; Vatle S
    Am Heart J; 1988 Dec; 116(6 Pt 2):1790-6. PubMed ID: 2904752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.